U.S. markets open in 4 hours 5 minutes

Aquestive Therapeutics, Inc. (AQST)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.1100-0.0400 (-3.48%)
At close: 04:00PM EDT
1.1000 -0.01 (-0.90%)
After hours: 07:08PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close1.1500
Bid0.0000 x 1000
Ask0.0000 x 3200
Day's Range1.0900 - 1.1500
52 Week Range0.6180 - 6.4000
Avg. Volume888,256
Market Cap59.219M
Beta (5Y Monthly)3.11
PE Ratio (TTM)N/A
EPS (TTM)-1.7470
Earnings DateOct 31, 2022 - Nov 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.36
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AQST

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Aquestive Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 09/28/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    9 days agoArgus Research
View more
  • Benzinga

    Aquestive Inks Supply Pact For Its Seizure Treatment Covering European, Middle East Countries

    Aquestive Therapeutics Inc (NASDAQ: AQST) entered a license and supply agreement with Pharmanovia for Libervant (diazepam) Buccal Film across the European Union, the U.K., Switzerland, and Norway, as well as countries in the Middle East and North Africa (MENA). Libervant is used to treat prolonged or acute, convulsive seizures of all ages. "Libervant has the distinct advantage of being readily administered when needed without regard to food, which is essential to patients as rapid and extensive

  • GlobeNewswire

    Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film for European and MENA Markets

    WARREN, N.J., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced it has entered a license, and supply agreement for Libervant™ (diazepam) Buccal Film with Pharmanovia, a global lifecycle management healthcare company, for treatment of prolonged or acute, convulsive seizures in

  • Benzinga

    Aquestive's AQST-109 Compares Favorably To Widely Used EpiPen For Severe Allergic Reaction

    Aquestive Therapeutics Inc (NASDAQ: AQST) announced positive topline results from the EPIPHAST 2 trial for its AQST-109 epinephrine sublingual film. The trial was designed to compare single doses of AQST-109 to EpiPen 0.3mg and epinephrine 0.3mg intramuscular (IM) injection and repeat doses of AQST-109 to repeat doses of epinephrine 0.3mg IM injection. EpiPen auto-injectors are used for allergic emergencies. Related: Aquestive Therapeutics Reveals Favorable Data From Epinephrine Trial For Allerg